Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Oxfendazole Development Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Oxfendazole in Mild Parenchymal Brain Cysticercosis
Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neurocysticercosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Oxfendazole Development Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fascioliasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Universidad Peruana Cayetano Heredia, Lima, Peru
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults
Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Trichuriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2018
Lead Product(s) : Fenbendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Universidad Peruana Cayetano Heredia, Lima, Peru
Deal Size : Inapplicable
Deal Type : Inapplicable